Can low-dose naltrexone help in cancer prevention?
Low-dose naltrexone (LDN) is a well-known opioid antagonist that’s used in alcohol and opioid abuse; however, in the last few years, LDN’s role in cancer research has increased as its believed that it has an upcoming role in cancer treatment and prevention, due to its effectiveness and its low adverse events when compared to conventional chemotherapeutic drugs.
Researchers performed various studies to test the hypothesis that LDN:
- Obtains direct antitumor activity.
- Potentiate immunological functions by internal immunomodulation.
- Minimize chemotherapeutic toxicity and adverse events without the need to decrease the chemotherapeutic drug dose.
- Improve the quality of life for terminal patients.
- Prevent tumor development.
LDN shows promising results for patients with breast cancer, colon cancer, pancreatic cancer, and prostate cancer, among others.
Read Full Article
https://www.welltopiarx.com/blog/the-promising-potential-of-low-dose-naltrexone-for-cancer-treatment/